

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/126089/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Mentasti, Massimo, Prime, Kerry, Sands, Kirsty, Khan, Swati and Wootton, Mandy 2019. Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from enterobacteriales and gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis. *European Journal of Clinical Microbiology and Infectious Diseases* 38 (11) , pp. 2029-2036. 10.1007/s10096-019-03637-5 file

Publishers page: <http://dx.doi.org/10.1007/s10096-019-03637-5>
<<http://dx.doi.org/10.1007/s10096-019-03637-5>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 Original Article

2

3 **Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from**
4 **Enterobacteriales and Gram negative non-fermenter bacteria by real time PCR and melt curve**
5 **analysis**

6

7

8 Authors:

9

10 Massimo Mentasti^{1*} - ORCID: 0000-0003-4530-7463

11 Kerry Prime¹ - ORCID: not applicable.

12 Kirsty Sands² - ORCID: not applicable.

13 Swati Khan¹ - ORCID: not applicable.

14 Mandy Wootton¹ - ORCID: not applicable.

15

16

17 Affiliations:

18

19 ¹ Specialist Antimicrobial and Chemotherapy Unit, Public Health Wales, University Hospital of
20 Wales, Heath Park, Cardiff, CF14 4XW, United Kingdom.

21

22 ² School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, United Kingdom.

23

24

25 * Corresponding author:

26

27 Email: massimo.mentasti@wales.nhs.uk

28 Tel.: +44 (0)2920 742163

29

30 Keywords: PCR, detection, carbapenemase, Enterobacteriales, non-Fermenter

31 **Abstract**

32

33 Carbapenemase producing microorganisms are increasingly isolated and often associated with
34 treatment failures and outbreaks. The need for reliable and timely detection and/or confirmation of
35 carbapenemase production is paramount, therefore a real-time PCR assay targeting IMP, NDM, VIM,
36 KPC and OXA-48-like carbapenemases was designed and validated.

37

38 All available allele variants of the above carbapenemases were downloaded from the Beta-Lactamase
39 DataBase (<http://bldb.eu/>), aligned with Clustal Omega and primers designed using Primer-BLAST.
40 Real-time PCR monoplexes were optimized for the QuantStudio 6-Flex (Applied Biosystems) using the
41 PowerUp SYBR Green Master Mix (Life Technologies) and validated using a panel of 204 characterised
42 strains carrying a wide range of beta-lactamases, sometimes in combination. Melt-curve analysis was
43 used to confirm positive results.

44

45 The *in silico* approach allowed primers to be designed in conserved regions of the KPC and NDM
46 alignments, while three primer sets for IMP and two for VIM were necessary to ensure amplification of
47 the different variants. One primer set was designed for OXA-48-like, however it is unlikely to detect all
48 variants. Expected results were obtained for all 204 tested strains, with 100% sensitivity and specificity.
49 Melt-curve analysis showed consistent T_m results for KPC, NDM and OXA-48-like; differences were
50 instead noted for IMP and VIM as likely consequence of higher variability in the PCR target regions.
51 Inhibition was not observed.

52

53 The assay is rapid, easy to perform and implement. It enables unequivocal detection of IMP, NDM, VIM,
54 KPC and OXA-48-like carbapenemases even when more than one type is present simultaneously.

55

56 Introduction

57

58 Carbapenems are amongst the last line of defence to treat serious bacterial infections. However,
59 carbapenemases (i.e. enzymes able to inactivate carbapenems) are increasingly identified in both
60 Enterobacterales and non-fermenter Gram-negative isolates. Carbapenemase producing organisms
61 (CPO) are frequently associated with treatment failure and outbreaks, with the latter worsened by the
62 fact that carbapenemases are often present on mobile genetic elements and can therefore easily spread
63 between different bacteria [1].

64 In Wales, IMP, NDM, VIM, KPC and OXA-48-like (known as the “big five”) are the carbapenemases
65 predominantly identified and consistent with those found in the rest of the UK: in particular, IMP, NDM,
66 KPC and OXA-48-like in Enterobacterales [2] and VIM in *Pseudomonas* species [3]. Phenotypic assays
67 employing inhibitors for the different enzymes are available for the detection of some carbapenemases.
68 For example IMP, NDM and VIM (Class B, metallo- β -lactamase) enzymes are inhibited by chelating
69 agents like ethylenediaminetetraacetic acid (EDTA) and dipicolinic acid (DPA), while KPC (class A β -
70 lactamase) is inhibited by boronic acid; an inhibitor for OXA-48-like (class D) β -lactamases has not yet
71 been identified, although temocillin resistance can be used as an indicator of its presence [4]. These
72 phenotypic tests are both sensitive and specific predominantly for Enterobacterales, while their
73 performance is poor for *Pseudomonas* species [5, 6, 7]. Furthermore, these tests require 24hrs
74 incubation to completion and can sometimes be difficult to interpret.

75 Carbapenemase screening in Enterobacterales is performed in Wales according to EUCAST criteria,
76 i.e. meropenem inhibition zone < 28mm and/or meropenem MIC > 0.125 mg/mL [4] with isolates flagged
77 as potential CPOs sent to the Specialist Antimicrobial Chemotherapy Unit (SACU), Cardiff (UK) for
78 further investigation. For *Acinetobacter* and *Pseudomonas* species all carbapenem and carbapenem
79 plus piperacillin/tazobactam resistant isolates are referred accordingly. In SACU, phenotypic
80 confirmation of carbapenem resistance is performed and carbapenemase production investigated using
81 Neo-Sensitabs™ combination disks (ROSCO, Denmark) and MBL IP/IMI (*Pseudomonas* only) and MBL
82 MP/IMI (Enterobacterales only) double ended E-Tests (bioMérieux, France), followed by in-house
83 block-based PCR to confirm positive results.

84 The number of isolates referred to SACU for carbapenemase confirmation doubled from approximately
85 250 to 500 per year between 2015 and 2018, with an accompanying 100% rise in the number of CPO

86 confirmed per year (from 19 to 38). Nevertheless, the incidence in Wales (population approximately
87 3,125,000 inhabitants estimated in June 2017 [8]) remains low when compared to data reported from
88 other Countries [9]. Referral numbers are predicted to rise further as hospitals undertake more rigorous
89 screening programmes to detect CPO in admission patients as per recommendations [10]. The increase
90 in requests for carbapenemase confirmation plus the importance of rapidly detecting CPO for effective
91 infection control management, demanded a development of the above described confirmatory approach
92 adopted by SACU. These methods are time consuming, labour intensive and involve the use of the
93 toxic and carcinogenic compound, ethidium bromide, to visualise PCR results by gel electrophoresis
94 (although safer intercalating agents are available nowadays). The need for a more rapid and reliable
95 approach has been identified with the aim to reduce the time to issue confirmatory reports and better
96 assist clinicians and infection control teams. Real-time PCR is a well-established methodology for
97 detecting genetic markers in bacteria. It can provide results much faster than block-based PCR and
98 does not normally require the use of high risk reagents. Therefore, a real-time PCR assay based on
99 SYBR Green chemistry has been designed to detect the “big five” carbapenemases and thoroughly
100 validated using a large panel of previously characterised Gram-negative isolates.

101

102

103 **Materials and Methods**

104

105 **Assay design**

106 IMP, NDM, VIM, KPC and OXA-48-like allele sequences were downloaded (as of December 2018) from
107 the Beta-Lactamase DataBase [11] and aligned using Clustal Omega [12]. Alleles with less than 90%
108 sequence identity to the rest of the alignment were excluded and separate primers were designed where
109 a strain carrying them was available to the authors for *in vitro* testing. Ten different primer sets per
110 target were designed using Primer-BLAST [13] and then compared to the relevant alignment to identify
111 the pair that at least *in silico* was able to amplify the highest number of alleles. Where necessary,
112 degenerate bases (a maximum of 2 per primer) were added to cover non-conserved positions. Primer
113 sequences and amplicon sizes are detailed in Table 1.

114

115 **Bacterial strains**

116 A total of 204 previously characterised Gram-negative isolates from 19 different *species* isolated world-
117 wide were selected from the Authors', Public Health England, NCTC and ATCC collections
118 (Supplementary data). One hundred and thirteen carried one of the "big five" carbapenemases while
119 22 carried two different markers simultaneously. The remaining 69 were negative for "big five"
120 carbapenemases however some carried genes for other β -lactamases (such as AmpC, CTX-M, GES,
121 IMI, L1 & L2, OXA-10, OXA-23, OXA-51, OXA-58, TEM, SHV, SME, SPM and VEB). The 135 "big five"
122 CPOs carried a total of 40 IMPs (including IMP-1, IMP-4, , IMP-6, IMP-7, IMP-8, IMP-10, IMP-11, IMP-
123 13, IMP-14, IMP-29 and IMP-62), 27 VIMs (including VIM-1, VIM-2, VIM-4, VIM-7, VIM-10, VIM-19 and
124 VIM-29), 31 NDMs (NDM-1, NDM-3, NDM-4, NDM-5, NDM-7), 26 KPCs (including KPC-2, KPC-3, KPC-
125 4 and KPC-23) and 33 OXA-48-like markers (including OXA-48, OXA-181, OXA-204, OXA-232, OXA-
126 244 and OXA-245).

127

128 After overnight aerobic growth on blood agar at $35\pm 1^\circ\text{C}$, bacterial growth approximately equivalent to a
129 third of a loopful (10 μL loop) was re-suspended in 250 μL of nuclease-free water and heat killed at
130 100°C for 10 min. Supernatant was separated by centrifugation at 12,000 g for 2 min and diluted 1:20
131 in nuclease-free water prior to testing. An extraction control (i.e. 250 μL of nuclease-free water) was
132 always included to discount cross contamination. A panel of seven strains was used as positive control
133 in every experiment, namely *Escherichia coli* NCTC 13476 (IMP_a), *Serratia marcescens* SACU 1212
134 (IMP_b), *Pseudomonas aeruginosa* SACU 1205 (IMP_c), *Klebsiella pneumoniae* NCTC 13440 (VIM),
135 *Klebsiella pneumoniae* NCTC 13443 (NDM), *Klebsiella pneumoniae* NCTC 13438 (KPC) and *Klebsiella*
136 *pneumoniae* NCTC 13442 (OXA-48).

137

138 **Internal process control**

139 An assay detecting a 76 bp fragment of the *green fluorescent protein*, *gfp* from *Aequorea victoria* [14]
140 was included to discount PCR inhibition. A custom-made plasmid (Eurofins, Germany) containing the
141 entire *gfp* sequence (Genbank Accession: M62653) was diluted to a working concentration of 1 pmol/ μL
142 before being added to the GFP reaction mix.

143

144 **Real Time PCR**

145 Monoplex PCR assays were optimized for the QuantStudio 6-Flex (Applied Biosystems) using the
146 PowerUp SYBR Green MasterMix (Life Technologies) and Microamp Fast Optical 96-Well Reaction
147 Plate 0.1 mL (Thermo-Fisher Scientific). Briefly, reactions were performed in a final volume of 10 μ L
148 containing 5 μ L of MasterMix, 2.5 μ L of template, 2 μ L of PCR grade water and 0.5 μ L of relevant primer
149 mix. The final concentration of each primer is listed in Table 2. The GFP reaction mix also contained
150 0.5 μ L per reaction of pGFP [1 pmol/ μ L], with 1.5 μ L of PCR grade water to make 10 μ L final volume.
151 After an initial uracil-DNA-glycosylase step at 50°C for 2 min, the Dual-Lock™ DNA polymerase was
152 activated at 95°C for 2 min followed by 35 cycles of denaturation at 95 °C for 1 sec and
153 annealing/extension at 60°C for 20 sec. Amplification results were analysed with the threshold set at
154 0.5 Δ Rn for all targets and the baseline set between 5 and 15 cycles only for the GFP target. Melting
155 curve analysis was performed as follows: 95°C for 15 sec (ramp rate = 1.6°C/sec), 60°C for 1 min (ramp
156 rate = 1.6°C/sec) and 95°C for 15 sec (ramp rate = 0.15°C/sec) with fluorescence fluctuation analysed
157 during the latter.

158

159

160 **Results**

161

162 ***In silico* analysis**

163

164 The *in silico* approach allowed primers to be designed within 100% conserved regions of the KPC and
165 NDM alignments. For the remaining carbapenemases, a single primer set able to amplify all alleles,
166 was not identified. Three primer sets (tested separately) were necessary to detect IMP variants and two
167 sets (tested in the same tube) for VIM variants. One primer set was designed for the OXA-48-like group,
168 however despite detecting the most common variants it is unlikely to detect OXA-54, OXA-436 and
169 OXA-535 due the suboptimal sequence identity (i.e. < 90%) to the rest of the group. . Clustal alignments
170 of PCR fragments with primers binding sites highlighted are available in the Supplementary data.

171

172 Thirty-seven KPC variants were listed on the Beta-Lactamase DataBase, however two sets (i.e. KPC-
173 1 & KPC-2 and KPC-9 & KPC-23) were identical while KPC-20 was “assigned” but no sequence was
174 available. Specific primers were designed in a conserved region of the remaining 34 KPC alleles. Primer

175 binding sites were 100% conserved and no single nucleotide polymorphisms (SNPs) were identified in
176 the region between the primers.

177

178 A specific primer set was designed in a conserved region of the alignment of all available 24 NDM
179 variants, with no exclusion. Primer binding sites were 100% conserved and only one SNP (found in
180 NDM-10) was identified in the region between the primers.

181

182 Among the 79 described IMP variants, six (i.e. IMP-36, IMP-39, IMP-46, IMP-50, IMP-57 and IMP-65)
183 appeared as “assigned” but no sequence was available. Moreover, IMP-8 and IMP-47 share identical
184 sequence, consequently, the actual number of analysed variants was 72. Clustal analysis showed
185 considerable sequence variability, therefore it was not possible to identify a single primer set able to
186 detect all alleles. The Clustal generated tree was arbitrarily split in three sections (Figure 1) and a set
187 of primers designed for each section (i.e. IMPa, IMPb and IMPc). Degenerate bases had to be inserted
188 in all six primer sequences to ensure amplification of different variants.

189

190 Among the 60 described VIM variants, VIM-21, VIM-22 and VIM-55 were “assigned” but no sequence
191 was available. VIM-7 showed low sequence identity with the rest of the alleles (e.g. 81% identity with
192 VIM-1), consequently it was excluded from the alignment. Specific primers were designed in a
193 conserved region of the remaining 56 VIM alleles and one degenerate base was introduced in the
194 forward primer. As previously mentioned, a separate set of primers was also designed specifically for
195 VIM-7 as this variant was available to the authors for *in vitro* testing.

196

197 Only OXA-48-like variants with a definitive assignment by NCBI (30 in total) were downloaded from the
198 Beta-Lactamase DataBase (i.e. OXA-48, OXA-54, OXA-162, OXA-163, OXA-181, OXA-199, OXA-204,
199 OXA-232, OXA-244, OXA-245, OXA-247, OXA-252, OXA-370, OXA-405, OXA-416, OXA-436, OXA-
200 438, OXA-439, OXA-484, OXA-505, OXA-514, OXA-515, OXA-517, OXA-519, OXA-535, OXA-538,
201 OXA-546, OXA-547, OXA-566 and OXA-657). After Clustal analysis, OXA-54, OXA-436 and OXA-535
202 were excluded from the alignment due to low sequence identity (84%, 84% and 85% respectively with
203 OXA-48). In this instance specific primers were not designed as they were not available to the authors
204 for *in vitro* testing. Primers for the remaining 27 OXA-48-like variants were designed in a conserved

205 region with one ambiguity introduced within the forward primer while the binding site of the reverse
206 primer was 100% conserved.

207

208 ***In vitro* analysis**

209

210 The eight monoplex real-time PCR assays (i.e. IMPa, IMPb, IMPc, NDM, VIM, KPC, OXA-48 and GFP)
211 were performed in 96-well plates with PCR mixes added in rows; DNA extracts were tested in column
212 1 to 10, while column 11 and 12 were used to test extraction and positive controls respectively. The
213 time necessary to complete PCR amplification and melt curve analysis was approx. 40min. Testing of
214 undiluted DNA extracts resulted in strong PCR inhibition (as revealed by absence of- or delayed GFP
215 amplification), consequently 1:20 dilutions were prepared prior to testing. Formation of primer dimers
216 was observed with the NDM assay, therefore oligonucleotide sequences were reviewed *in silico* and
217 concentrations decreased *in vitro* to improve results (Table 2).

218

219 DNA extracts of *Escherichia coli* NCTC 13476 (IMP), *Klebsiella pneumoniae* NCTC 13440 (VIM-1),
220 *Klebsiella pneumoniae* NCTC 13443 (NDM-1), *Klebsiella pneumoniae* NCTC 13438 (KPC-3) and
221 *Klebsiella pneumoniae* NCTC 13442 (OXA-48) were mixed to generate all possible target combinations
222 (for simplicity only IMPa among the three IMP primer sets was included in this analysis). In all cases,
223 the assay successfully detected all the carbapenemases present in the reaction mix, regardless of if
224 only one or all five were present simultaneously (Supplementary data).

225

226 Melt-curve analysis was used to confirm positive results by comparing dissociation curves to that of the
227 relevant positive control. Minor T_m variations were observed for NDM, VIM, KPC, OXA-48-like and GFP
228 ($0.15 < \text{St Dev} < 0.30$), while greater differences were noted with the three IMP monoplexes ($0.49 < \text{St}$
229 $\text{Dev} < 0.62$).

230

231 The expected result was initially obtained for 203 of the 204 previously characterised isolates. *Klebsiella*
232 *pneumoniae* SACU 27698 was meant to be negative for the “big five” carbapenemases, instead it
233 produced unequivocal amplification with IMPa (Ct = 17.49) and IMPb (Ct = 30.49) primer sets and
234 melting curves consistent with those of *E. coli* NCTC 13476 and *S. marcescens* SACU 1212 (i.e. IMPa

235 and IMPb positive controls). Further analysis with in-house block-based PCR confirmed presence of
236 IMP metallo- β -lactamase, while Whole Genome Sequencing (WGS) by MiSeq (Illumina) characterised
237 it as IMP-4 (data not shown). Indeed, the newly designed assay provided the expected result for all 204
238 tested isolates (100% sensitivity and specificity) including those carrying two “big five” carbapenemases
239 simultaneously. Cross-reaction with the other resistance markers present in the above mentioned
240 isolates was not observed.

241

242 Overall, amplification results produced mean Ct values of ca. 16 and Standard Deviation (SD) values
243 between 0.88 and 1.45 (Table 3). Among the 40 isolates carrying IMP markers, 36 gave positive results
244 with two of the three IMP primer sets used (i.e. a strong result in the expected Ct range and a weak
245 result with Ct > 25 respectively). IMP alleles from part A of the Clustal generated tree gave strong IMPa
246 results and weak IMPb results, alleles in part B gave strong IMPb results and weak IMPc results, while
247 alleles in part C of the tree gave IMPc strong results and weaker IMPb results (Supplementary data).
248 Four IMPs of which three IMP-13, were only amplified by one set of primers.

249

250

251 **Discussion**

252

253 We describe here the design and validation of an array of monoplex real-time PCRs optimised for the
254 QuantStudio 6-flex platform (ThermoFischer Scientific) to rapidly detect and differentiate the “big five”
255 carbapenemases, (i.e. IMP, NDM, VIM, KPC and OXA-48) from Enterobacteriales and non-fermenter
256 Gram-negative isolates. A rational approach that took into account all the relevant allele sequences
257 available from the Beta-Lactamase Database (as of December 2018) was applied *in silico* to design
258 specific primers and to then predict whether they would also detect those allele variants that were not
259 available to the authors for *in vitro* testing. A wide collection of previously characterised Gram-negative
260 isolates was then tested *in vitro* to fully validate the newly designed monoplexes. An assay targeting
261 the *gfp* [14] was simultaneously tested as an internal control to discount inhibition.

262

263 As resistance markers (especially IMP in this case) evolve rapidly causing emergence of new allele
264 variants, SYBR Green chemistry combined with melting curve analysis in monoplex PCR reactions was

265 chosen over multiplexing with primers and probes. Newly described SNPs in primers and/or probe
266 binding sites would potentially result in assays having to be redesigned and then revalidated. This is
267 time consuming and costly. The absence of probes in this assay reduces the number of binding sites
268 from three to two and consequently the likelihood that a newly described SNP falls into them. If indeed
269 a new SNP is identified in either of the two primer binding sites and it is decided that they need to be
270 redesigned, the use of separate monoplexes allows to limit the revalidation to just the affected monoplex
271 instead of having to perform a major revalidation like when a multiplex approach is used. Furthermore,
272 the use of separate monoplexes provides greater flexibility to combine testing of different panels of
273 targets if the need arises: one or more of the monoplexes described here could be quickly replaced with
274 others validated separately to detect different resistance markers (e.g. GIM, SIM, SPM, IMI, etc) without
275 the need to perform any further validation on the entire assay panel.

276

277 The *in silico* analysis showed that this assay should be able to detect all the IMP, NDM, VIM and KPC
278 variants described as of December 2018. Among the OXA-48-like group, OXA-54 and OXA-535,
279 described in the chromosome of *Shewanella species* [15, 16] and OXA-436 identified on a plasmid in
280 *Enterobacter species*, *Citrobacter species* and *K. pneumoniae* in Denmark [17] are unlikely to be
281 detected.

282

283 The *in vitro* experiments proved the assay to be 100% sensitive and specific on a large panel of
284 previously characterised isolates available to the authors. As stated by Lund *et al.* (2018), assays are
285 often validated using a limited selection of target variants that are available locally; furthermore, testing
286 high numbers of unsequenced isolates might simply result in redundant analysis of a small number of
287 variants which then provides little indication about the actual sensitivity and specificity of a particular
288 assay. These issues were addressed in this study by applying a robust *in silico* approach to confidently
289 predict amplification of those variants that were not available for *in vitro* testing and by then including
290 (where possible) isolates where the “big five” allele variant had previously been characterised (i.e. by
291 Sanger sequencing and/or by WGS).

292

293 Interpretation of melting profiles can be problematic when dissociation curves do not overlap with that
294 of the positive control. This was often observed with isolates carrying IMP genes as a likely

295 consequence of high sequence variability of the IMP PCR products. Nevertheless, when an IMP allele
296 was present, more than one primer set was often able to detect it (usually two primers sets, one
297 producing a strong result with Ct between 14 and 18, and another producing Ct > 18) allowing confident
298 identification of true positives. It is noteworthy that variations in T_m results were observed also for those
299 PCR products that were not meant to contain any SNP (e.g. KPC and GFP) therefore it seems that the
300 actual T_m value cannot be reproducibly obtained by the PCR platform between different PCR runs. A
301 T_m standard deviation of 0.20 was calculated for the GFP amplified fragment (which is identical in every
302 PCR run) and this value could be considered as an indication of the T_m uncertainty of measurement
303 intrinsic to this procedure. Different T_m values were also noted for VIM alleles, however in this case, it
304 was due to VIM-7 being quite different (only 81% nucleotide identity with VIM-1), with a T_m of approx.
305 84°C compared to T_m of approx. 81°C for the remaining VIM alleles. This was consistently observed
306 and was actually helpful to differentiate between VIM-7 and the other VIM alleles.

307

308 In at least one instance, the assay provided more sensitive and reliable results than standard phenotypic
309 analysis: *K. pneumoniae* SACU 27698 previously characterised as negative for the “big five”
310 carbapenemases, was instead found to be IMP positive and later characterised by WGS to carry IMP-
311 4. This result triggered an investigation that identified the above isolate as part of a cluster involving five
312 patients (data not shown) which clearly proves the added value of the here described real time PCR
313 assay. Retrospective analysis on the isolate showed that combination disks did not to show metallo-β-
314 lactamase activity (i.e. only 2 mm difference between the meropenem and the meropenem/DPA disks)
315 while the MP/MPI double-ended strip provided a weakly positive result (MIC ratio = 12). With this in
316 mind, it was decided to modify the SACU approach for investigation of carbapenemases. The real time
317 PCR assay described here became the first line method to investigate presence of the “big five”
318 carbapenemases. Positive PCR results are reported immediately without performing further analysis,
319 however as negative PCR results cannot completely exclude presence of a carbapenemase, further
320 investigations need to be performed. As already mentioned, new “big five” allele variants might not be
321 detected by this assay or a carbapenemase not included in this assay (e.g. GIM, SIM, SPM, etc) could
322 be present. Finally, novel carbapenemases, not known as yet, would equally not be detected.
323 Therefore, all PCR negative isolates are tested with combination disks and double ended strips to
324 phenotypically exclude both carbapenemase and Extended Spectrum β-lactamase (ESBL) activity

325 before negative results are reported. In those cases where carbapenemase activity is observed despite
326 a negative PCR results, alternative methods (such as sequence analysis) would be applied to
327 investigate the cause of the resistant phenotype.

328

329 In certain cases, “big five” variants detected by this assay might actually confer either weak or
330 undetectable level of carbapenemase resistance. Indeed, KPC-14 and KPC-28 have been
331 demonstrated to have reduced carbapenemase activity [19] while OXA-163, OXA-247 and OXA-405
332 have been shown to have no carbapenemase activity [20, 21] due to amino acid deletions in the active
333 site. Isolates carrying these variants are likely to generate discrepant PCR and phenotypic results thus
334 further testing (e.g. sequence analysis of the “big 5” variant) should be performed. In particular, KPC-
335 28 has also been characterised to have an amino acid substitution (i.e. H274Y) causing a 50-fold
336 increase in ceftazidime hydrolysis and consequently high MIC to ceftazidime/avibactam, an effective
337 antimicrobial option for KPC producing bacteria [19].

338

339 The assay described herein allows testing of 10 isolates at a time (plus extraction control and positive
340 control) using 96-well plates. Given the short PCR running time (ca. 40 min), DNA could be extracted
341 simultaneously from a greater number of isolates to allow a quick second PCR experiment to be
342 prepared while the first is running; up to 20 isolates could be then tested in less than 90 min.
343 Alternatively, for high through put 384-well plates may be used, allowing up to 46 strains (plus controls)
344 to be tested simultaneously. The assay was deemed easy to perform by members of staff with little or
345 no experience with real-time PCR and melt-curve analysis. Importantly, the real time PCR assay
346 allowed unequivocal result interpretation even when more than one “big five” carbapenemase
347 resistance marker was present. Finally, the new algorithm improved the reference service by reducing
348 the time necessary to report positive results and at the same time reducing the risk of reporting false-
349 negative results.

350

351 In summary the assay was easily implemented, allowed faster and more reliable positive results than
352 previously obtained by SACU to be available for clinicians and infection control specialists. The potential
353 wider benefits of the assay include reducing costs to the hospital from keeping potential positive patients

354 in side rooms, inappropriate therapy of positive patients and increased screening costs because of
355 delays in positive results.

356

357

358 **Acknowledgement**

359 The authors would like to thank Daniele Meunier (Public Health England) for providing part of the strain
360 collection that was used in this study and Michael Perry (Public Health Wales) for constructive
361 comments on the manuscript. Results of this study were presented at the 29th ECCMID, Amsterdam,
362 The Netherlands 13-16 April 2019 (Poster n. 1234).

363

364

365 **Compliance with Ethical Standards**

366

367 **Funding.** No funding was received to perform this study.

368 **Conflict of interest.** The authors declare that they have no conflict of interest.

369 **Ethical approval.** Not required for this study.

370 **Informed consent.** Not required for this study.

371 **References**

372

373 1. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF (2018)
374 Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis 66(8):1290-1297.

375

376 2. Woodford N, Xu-McCrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F,
377 Donaldson H, Rao GG, Verma A, Wareham DW, Ciesielczuk H, Stone GG, Irani PM, Bracher S,
378 Hawkey PM (2018) Prevalence of carbapenem resistance and carbapenemase production
379 among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem
380 Resistance Evaluation Surveillance Trial (iCREST-UK). J Antimicrob Chemother 73(3):698-702.

381

382 3. Wright, LL, Turton, JF, Livermore DM, Hopkins KL, Woodford N (2015) Dominance of
383 international 'high-risk clones' among metallo-β-lactamase- producing *Pseudomonas aeruginosa*
384 in the UK. J Antimicrob Chemother 70:103-110.

385

386 4. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical
387 and/or epidemiological importance. Available online at:
388 http://www.eucast.org/resistance_mechanisms. Accessed 28 May 2019.

389

390 5. Hansen F, Hammerum AM, Skov R, Haldorsen B, Sundsfjord A, Samuelsen O (2014) Evaluation
391 of the total MBL confirm kit (ROSCO) for detection of metallo-β-lactamases in *Pseudomonas*
392 *aeruginosa* and *Acinetobacter baumannii*. Diagn Microbiol Infect Dis 79(4):486-488.

393

394 6. Lee K, Lim YS, Yong D, Yum JH, Chong Y (2003) Evaluation of the Hodge test and the imipenem-
395 EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of
396 *Pseudomonas spp.* and *Acinetobacter spp.* J Clin Microbiol 41:4623-4629.

397

398 7. Samuelsen Ø, Buaro L, Giske CG, Simonsen GS, Aasnaes B, Sundsfjord A (2008) Evaluation of
399 phenotypic tests for the detection of metallo-β-lactamase-producing *Pseudomonas aeruginosa*
400 in a low prevalence country. J Antimicrob Chemother 61(4):827-30.

401

- 402 8. Wales population mid-year estimate. Available online at:
403 www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/timeseries/wapop/pop. Accessed on 28 May 2019.
404
- 405 9. Antimicrobial Resistance in Wales 2008-2017. Available online at:
406 www.wales.nhs.uk/sitesplus/documents/888/Antimicrobial%20Resistance%20in%20Wales%202008-2017%20v1.pdf. Accessed on 28 May 2019.
407
408
409
- 410 10. Carbapenemase-producing Enterobacteriaceae: acute trusts toolkit. Available online at:
411 <https://www.gov.uk/government/publications/carbapenemase-producing-enterobacteriaceae-early-detection-management-and-control-toolkit-for-acute-trusts>. Accessed on 28 May 2019.
412
413
- 414 11. Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P, Iorga BI (2017) Beta-Lactamase DataBase (BLDB) – Structure and Function. *J. Enzyme Inhib Med Chem* 32:
415 917-919.
416
417
- 418 12. Chojnacki S, Cowley A, Lee J, Foix A, Lopez R (2017) Programmatic access to bioinformatics
419 tools from EMBL-EBI update: 2017. *Nucleic Acids Res* 45(W1):W550-W553.
420
- 421 13. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL (2012) Primer-BLAST: a
422 tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics* 13:134.
423
- 424 14. Murphy NM, McLauchlin J, Ohai C, Grant KA (2007) Construction and evaluation of a
425 microbiological positive process internal control for PCR-based examination of food samples for
426 *Listeria monocytogenes* and *Salmonella enterica*. *Int J Food Microbiol* 120:110-119.
427
- 428 15. Poirel L, Héritier C, Nordmann P (2004) Chromosome-encoded ambler class D beta-lactamase
429 of *Shewanella oneidensis* as a progenitor of carbapenem-hydrolyzing oxacillinase. *Antimicrob*
430 *Agents Chemother* 48:348-51.

- 431 16. Dabos L, Jousset AB, Bonnin RA, Fortineau N, Zavala A, Retailleau P, Iorga BI, Naas T (2018)
432 Genetic and Biochemical Characterization of OXA-535, a Distantly Related OXA-48-Like β -
433 Lactamase. *Antimicrob Agents Chemother* 62(10).
434
- 435 17. Samuelsen Ø, Hansen F, Aasnæs B, Hasman H, Lund BA, Leiros HS, Lilje B, Janice J, Jakobsen
436 L, Littauer P, Søres LM, Holznecht BJ, Andersen LP, Stegger M, Andersen PS, Hammerum AM
437 (2017) Dissemination and Characteristics of a Novel Plasmid-Encoded Carbapenem-Hydrolyzing
438 Class D β -Lactamase, OXA-436, Found in Isolates from Four Patients at Six Different Hospitals
439 in Denmark. *Antimicrob Agents Chemother* 62(1).
440
- 441 18. Lund M, Petersen MB, Jørgensen AL, Paulmann D, Wang M (2018) Rapid real-time PCR for the
442 detection of IMP, NDM, VIM, KPC and OXA-48 carbapenemase genes in isolates and spiked
443 stool samples. *Diagn Microbiol Infect Dis* 92:8-12.
444
- 445 19. Oueslati S, Iorga BI, Tiili L, Exilie C, Zavala A, Dortet L, Jousset AB, Bernabeu S, Bonnin RA,
446 Naas T (2019) Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking
447 carbapenemase activity. *J Antimicrob Chemother* doi: 10.1093/jac/dkz209.
448
- 449 20. Dortet L, Oueslati S, Jeannot K, Tandé D, Naas T, Nordmann P (2015) Genetic and biochemical
450 characterization of OXA-405, an OXA-48-type extended-spectrum β -lactamase without
451 significant carbapenemase activity. *Antimicrob Agents Chemother* 59:3823-8.
452
- 453 21. Dortet L, Naas T (2017) Noncarbapenemase OXA-48 Variants (OXA-163 and OXA-405) Falsely
454 Detected as Carbapenemases by the β Carba Test. *J Clin Microbiol* 55:654-655.
455

456 **Table 1.** Summary of primer sets used in this study (FP = Forward Primer; RP = Reverse Primer;
 457 ambiguities are underlined; * VIM and VIM-7 tested in the same tube).
 458

Primer set	Target	Name	Sequence (5'→3')	Amplicon (bp)	Reference
1	IMP(a)	IMP _a _FP	TGACGCAAATDTAGAAGCTTGGC	101	This study
		IMP _a _RP	CRTCTCCARCTTCACTGTGAC		
2	IMP(b)	IMP _b _FP	GAYGCCTATCTRATTGACACTCC	79	This study
		IMP _b _RP	TATARCCGCGCTCMACAAACCA		
3	IMP(c)	IMP _c _FP	<u>K</u> GAYGCAAATTTAGAAGCTTGGCCA	142	This study
		IMP _c _RP	CCCTTTAACAGCCTGYTCCCA		
4	NDM	NDM_FP	CAACTTTGGCCCGCTCAAGG	100	This study
		NDM_RP	GCAGCCACCAAAAAGCGATGT		
5*	VIM	VIM_FP	CGAAAAACACAGCGGCMCTTCT	73	This study
		VIM_RP	GTGGAGACTGCACGCGTTAC		
	VIM-7	VIM-7_FP	GGTGGCTGTGCAGTTCATGAG	122	This study
		VIM-7_RP	ACGACCTCTGCTTCCGGATAC		
6	KPC	KPC_FP	CCACTGGGCGCGCACCTATT	51	This study
		KPC_RP	TGTTAGGCGCCCGGGTGTAG		
7	OXA-48-like	OXA-48_FP	CTGGTGGGTYGGTTGGGTTGA	89	This study
		OXA-48_RP	GCAGCCCTAAACCATCCGATGT		
8	GFP	GFP_FP	CCTGTCCTTTTACCAGACAACCA	76	[14]
		GFP_RP	GGTCTCTCTTTTCGTTGGGATCT		

459

460 **Table 2.** Final concentration of primers used in this study (* VIM and VIM-7 tested in the same tube).

Primer set	Target	Primer Name	Final Conc. [nM]
1	IMPa	IMP(a)_FP	500
		IMP(a)_RP	500
2	IMPb	IMP(b)_FP	500
		IMP(b)_RP	500
3	IMPC	IMP(c)_FP	500
		IMP(c)_RP	500
4	NDM	NDM_FP	300
		NDM_RP	300
5*	VIM	VIM_FP	400
		VIM_RP	400
	VIM-7	VIM7_FP	100
		VIM7_RP	100
6	KPC	KPC_FP	500
		KPC_RP	500
7	OXA-48-like	OXA-48_FP	400
		OXA-48_RP	400
8	GFP	GFP_FP	300
		GFP_RP	300

461


462 **Table 3.** Summary of Cycle threshold (Ct) and melting temperature (Tm) results for the primer sets
 463 used in this study (* VIM and VIM-7 tested in the same tube; ** only one strain containing VIM-7 was
 464 available for testing, consequently Min, Max and SD were not calculated).

465

Primer set	Target	Ct				Tm (°C)			
		Min	Mean	Max	SD	Min	Mean	Max	SD
1	IMPa	14.67	16.73	20.35	1.43	76.92	77.74	78.47	0.49
2	IMPb	14.43	16.66	18.94	1.45	75.13	76.31	77.21	0.77
3	IMPC	14.88	16.06	16.98	0.88	76.92	77.51	78.06	0.62
4	NDM	13.73	16.41	18.83	0.99	84.61	84.86	85.58	0.21
5*	VIM	14.11	16.09	18.23	0.95	80.43	80.73	81.07	0.15
	VIM-7**	-	15.49	-	-	-	84.12	-	-
6	KPC	13.52	16.81	18.50	1.13	82.90	83.40	83.83	0.30
7	OXA-48-like	13.63	16.16	18.60	1.21	78.05	78.26	78.78	0.18
8	GFP	21.36	23.36	24.28	0.44	77.51	77.77	78.83	0.20

466

467 **Figure 1.** Clustal Omega generated tree of the IMP alleles available from the Beta-Lactamase
 468 DataBase.



469